Home Public Health AI-Powered Hong Kong Biotech Startup Raises $60 Million From Top VCs Including B Capital, Qiming

AI-Powered Hong Kong Biotech Startup Raises $60 Million From Top VCs Including B Capital, Qiming

by Enochadmin

Hong Kong-based biotech startup Insilico Drugs has raised $60 million in Collection D funding from buyers together with Singapore billionaire Eduardo Saverin’s B Capital Group, personal fairness large Warburg Pincus and Midas Lister Nisa Leung’s Qiming Enterprise Companions.

Different buyers within the spherical embody Pavilion Capital, a wholly-owned subsidiary of Singapore’s state investor Temasek, and BHR Companions, a Chinese language personal fairness agency that has backed the likes of ride-hailing large Didi and electrical automobile battery maker CATL.

ADVERTISEMENT

So far, Insilico Drugs has raised greater than $360 million, together with a Collection C funding round of $255 million in June final 12 months. The Collection C spherical included buyers Sequoia Capital China, Baidu Ventures, Korean billionaire Park Hyeon-joo’s Mirae Asset Capital and former Google China chief Kai-Fu Lee’s Sinovation Ventures.

The Collection D funding spherical is “a testomony to the power of our end-to-end AI platform, which has been validated by many companions, and produced our first novel antifibrotic program found utilizing AI and getting older analysis, and designed utilizing our generative AI chemistry engine,” Alex Zhavoronkov, founder and CEO of Insilico Drugs, stated in a statement on Monday.

A part of the cash raised will likely be used for the continued growth of Pharma.AI, Insilico Drugs’s software program platform that helps with drug evaluation and experimentation. The funds will even be used to develop a completely automated, AI-driven robotic drug discovery laboratory and totally robotic organic knowledge manufacturing facility, Insilico Drugs stated within the assertion.

ADVERTISEMENT

“The applying of synthetic intelligence and machine studying for drug discovery has unbelievable potential to remodel the way in which new therapies are developed,” stated Min Fang, managing director and head of China healthcare at Warburg Pincus, within the assertion.

Headquartered in Hong Kong and with an workplace in New York, Insilico Drugs makes use of AI to hurry up drug analysis for illnesses like most cancers. Earlier than beginning Insilico Drugs in 2014, Zhavoronkov based Deep Longevity, one other AI-powered healthcare startup in Hong Kong.

Source link

Related Articles

Leave a Comment